Resilient US Rebif, Gonal-f Q2 Sales Allow German Merck To Up Forecast
Executive Summary
Solid US demand for Gonal-f fertility and Rebif MS drugs in the second quarter – along with commissions from its Xalkori co-promotion partnership there with Pfizer – let Merck KGaA upgrade its guidance for the full year.
You may also be interested in...
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Interview: German Merck Set For Big "Leap" In India
Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.